Bromocriptine and Its Use in Parkinsonism

Journal of the American Geriatrics Society

Volumn 29, Issue 6, 1981, Pages 251-258

  HOEHN, MARGARET M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR; LEVODOPA;

CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DOPAMINE H 3; DRUG THERAPY; HALOPERIDOL H 3; MAJOR CLINICAL STUDY; PARKINSONISM; SHORT SURVEY; THERAPY;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; COMPARATIVE STUDY; HUMAN; LEVODOPA; PARKINSON DISEASE;

EID: 0019498182     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1981.tb02187.x     Document Type: Article

References (103)

1. Ergotoxine inhibition of deciduoma formation and its reversal by progesterone
2. 2‐Br‐alpha‐ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte
3. The inhibition of prolactin secretion in man by CB 154(2‐Br‐alpha‐ergocryptin)
4. Suppression of puerperal lactation with an ergot alkaloid: a double blind study
5. Controlled trial of bromocriptine, quinoestrol and placebo in suppression of puerperal lactation
6. Treatment of non‐puerperal galactorrhea with an ergot alkaloid
7. Long‐term treatment of galactorrhoea and hypogonadism with bromocriptine
8. Effects of 2‐bromo‐alpha‐ergocryptine and pimozide on growth hormone secretion
9. Long‐term treatment of acromegaly with bromocriptine
10. The influence of levodopa and adrenergic blockade on growth hormone and prolactin secretion in the MStTW15 tumor bearing rat
11. Bromocriptine and spasmotic torticollis
12. Successful use of bromocriptine in the treatment of a patient with chronic portosystemic encephalopathy
13. Treatment of anorexia nervosa by levodopa
14. Treatment of mania with bromocriptine
15. Idiopathic oedema and prolactin
16. The effect of bromocriptine in patients with benign prostatic hypertrophy
17. The use of bromocriptine in the treatment of the unstable bladder
18. Bromocriptine and hypertension
19. Cited by Parkes JD: Bromocriptine
20. Bromocriptine in Nelson's syndrome and Cushing's disease
21. Effects of bromocriptine in pituitary dependent Cushing's syndrome
22. Effect of anterior pituitary perfusion and intraventricular injection of catecholamines on prolactin release
23. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons
24. The inhibitory action of dopamine on neurones of the caudate nucleus
25. Caudate nucleus neurones: correlation of the effects of substantia nigra stimulation with iontophoretic dopamine
26. Dopaminergic involvement in hypothalamic function: extrahypothalamic and hypothalamic control. A neuroanatomical analysis
27. Receptor‐mediated control of dopamine metabolism
28. Dopamine is an important neurotransmitter in the human nervous system
29. Dopaminephilic properties of ergot alkaloids
30. Action of dopamine receptor agonists in forebrain and hypothalamus: rotational behavior, ovulation, and dopamine turnover
31. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)‐amphetamine, and l‐dopa
32. Effect of ergot drugs on central 5‐hydroxytryptamine neurones
33. Bromocriptine in parkinsonism
34. Essai de traitement de la maladie de Parkinson par la bromocryptine (CB 154 Sandoz)
35. Effect of CB154 (2‐bromo‐alpha‐ergocryptine) on paralysis agitans compared with Madopar in a double‐blind, cross‐over trial
36. Studies with bromocriptine
37. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease
38. Plasma dopa levels and growth hormone response to levodopa in parkinsonism
39. Studies with bromocriptine. III. Concomitant administration of caffeine to patients with idiopathic parkinsonism
40. Bromocriptine and levodopa (with and without carbidopa) in parkinsonism
41. Bromocriptine treatment in Parkinson's disease
42. Bromocriptine in parkinsonism: long‐term treatment, dose response, and comparison with levodopa
43. Plasma dopa levels and growth hormone response to levodopa in parkinsonism
44. Some aspects of dopamine in the basal ganglia
45. Bromocriptine in parkinsonism
46. Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine
47. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease
48. Bromocriptine in parkinsonism: a long‐term study
49. A double‐blind trial of bromocriptine in Parkinson's disease
50. Klinische Erfahrungen mit Bromocriptin, einem zentralen Dopaminergen
51. Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry
52. Brain dopamine receptor stimulation and the relief of parkinsonism: relationship between bromocriptine and levodopa
53. Treatment of parkinsonism with bromocriptine
54. Chorea and torsion in parkinsonism
55. Long term treatment of parkinsonism with bromocriptine
56. Traitement de la maladie de Parkinson par la bromocriptine
57. Bromocriptine et maladie de Parkinson: premiers résultats
58. EEG sleep study in parkinsonian patients under bromocryptine treatment
59. Comparison between lergotrile and bromocriptine in parkinsonism
60. Studies with bromocriptine. Part I. “On‐off” phenomenon
61. Bromocriptine alone or associated with l‐dopa plus benserazide in Parkinson's disease
62. Bromocriptine in Parkinson's disease
63. Long‐term treatment of Parkinson's disease with bromocriptine
64. Bromocriptine in parkinsonism
65. Bromocriptine in Parkinson's disease. Further studies
66. Long‐term efficacy of bromocriptine in Parkinson's disease
67. Bromocriptine in Parkinson's disease
68. Bromocriptine in parkinsonism
69. Efficacité de la bromocriptine chez deux parkinsoniens levodopa résistants
70. The antiparkinsonian efficacy of bromocriptine
71. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease
72. The role of bromocriptine in the treatment of parkinsonism
73. Treatment of Parkinson's disease with bromocriptine
74. Comparison of reflex effects of levodopa and bromocriptine in parkinsonism
75. Traitement des syndromes parkinsoniens par la bromocriptine
76. Bromocriptine in the treatment of advanced parkinsonism
77. Dopamine agonist Ro8–4650 in Parkinson's disease
78. Bromocriptine in levodopa response‐losing parkinsonism. A double blind study
79. Bromocriptine in lieu of levodopa for Parkinson's disease
80. On‐off effects in patients with Parkinson's disease on chronic levodopa therapy
81. An ergot derivative in the treatment of Parkinson's disease
82. Effect de la bromocriptine sur les fluctuations thérapeutiques secondaires à la dopathérapie. Phénomènes “on‐off” chez les parkinsoniens
83. Bromocriptine in parkinsonism
84. Le CB 154 dans le traitement de la maladie de Parkinson. Résultats d'une association avec la l‐dopa+idd
85. Treatment of the on‐off syndrome in parkinsonism with low dose bromocriptine in combination with levodopa
86. Myoclonic attacks induced by l‐dopa and bromocriptine in Parkinson patients: a sleep EEG study
87. Overview of present day treatment of Parkinson's disease
88. Advances in the neuropharmacology of parkinsonism
89. Hemiparkinsonism. A human model for studying dopaminergic sensitivity
90. Transfer of bromocriptine across the blood‐brain barrier in man
91. Plasma bromocriptine levels, clinical and growth hormone responses in parkinsonism
92. Idiopathic parkinsonism treated with bromocriptine
93. Bromocriptine
94. The cardiovascular effect of bromocriptine in parkinsonism
95. Digital vasospasm with bromocriptine
96. Parkinsonism ‐ New drugs and new approaches
97. Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease
98. Psychosis in patient on bromocriptine and levodopa with carbidopa
99. Effetti endocrini della bromocriptine in soggetti Parkinsoniani
100. Changes in pituitary hormones serum levels in bromocryptine‐treated parkinsonian patients
101. Endocrine aspects of bromocriptine therapy in parkinsonism
102. Bromocriptine and thyroid‐stimulating hormone secretion
103. Growth‐hormone response to bromocriptine in parkinsonism